2H0A.MU Stock Analysis
2H
Uncovered
Exicure Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 29 full-time employees. The company went IPO on 2018-05-09. The company is developing nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. The company is engaged in the development of its preclinical program targeting SCN9A for neuropathic pain; to develop SNA-based treatments in neuroscience targeting Huntingtons disease and Angelman syndrome; to develop Spherical Nucleic Acid (SNA)-based treatments for hair loss disorders; as well as the continued research and development of other therapeutic product candidates. SCN9A is its lead program candidate for the treatment of chronic pain. Cavrotolimod (AST-008) is a toll-like receptor 9 (TLR9), agonist designed for immuno-oncology applications utilizing its SNA technology. Its therapeutic discovery and development efforts are supported by its SNA technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid molecules that are radially arranged in three dimensions.